Netazepide, a gastrin/CCK2receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects
| Autor: | J W Black, Steve Warrington, Malcolm Boyce |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pharmacology
Agonist medicine.medical_specialty medicine.drug_class business.industry digestive oral and skin physiology Antagonist Placebo Crossover study Pentagastrin Endocrinology Competitive antagonist Drug tolerance Internal medicine medicine Pharmacology (medical) business hormones hormone substitutes and hormone antagonists Gastrin medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 76:689-698 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/bcp.12099 |
| Popis: | Aims To confirm by means of pentagastrin, a synthetic gastrin agonist, that netazepide is a gastrin/CCK2 receptor antagonist in healthy subjects, and that antagonism persists during repeated dosing. Methods We did two studies in which we infused pentagastrin (0.6 μg kg−1 h−1 intravenously), aspirated gastric secretion and measured the volume, pH and H+ secretion rate of the gastric aspirate. First, we did a double-blind, five-way crossover study (n = 10) to assess the effect of single oral doses of netazepide (1, 5, 25 and 100 mg) and placebo on the response to pentagastrin. Then, we did a single-blind, placebo-controlled study (n = 8) to assess the effect of the first and last oral doses of netazepide (100 mg) twice daily for 13 doses on the response to pentagastrin. Results Netazepide was well tolerated. After placebo, pentagastrin increased the volume and H+ secretion rate and reduced the pH of gastric aspirate. Compared with placebo, single doses of netazepide caused dose-dependent inhibition of the pentagastrin response (P < 0.02); netazepide (100 mg) abolished the response. After 13 doses, the reduction in volume and H+ secretion rate persisted (P < 0.001), but the pH effect was mostly lost. Conclusions Netazepide is an orally active, potent, competitive antagonist of human gastrin/CCK2 receptors. Antagonism is dose dependent and persists during repeated dosing, despite tolerance to the effect on pH. Further studies are required to explain that tolerance. Netazepide is a tool to study the physiology and pharmacology of gastrin, and merits studies in patients to assess its potential to treat gastric acid-related conditions and the trophic effects of hypergastrinaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text